Gilead Sciences Spain
在场
Gilead Sciences Spain 的所有者是 Gilead Sciences.
是其中之一......
Gilead Sciences 是一家在股票代码 GILD (US) 下上市的公司。
Gilead Sciences 在 7 个国家有直接业务。Gilead Sciences 拥有 7家子公司，其中包括 Gilead Sciences Canada、Gilead Sciences EMEA 和 Gilead Sciences Germany。
他们在：
涉及Gilead Sciences的并购和融资。
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (公布2024二月15号).
- Gilead Sciences has announced the acquisition of MiroBio (公布2022八月5号).
生物技术
Gilead Sciences 拥有 2,275 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Nurix Therapeutics 刚刚宣布为 175 筹款数百万美元。 (公布2024四月13号).
- Nuvation Bio has announced the acquisition of AnHeart (公布2024四月12号).
生物技术 行业的其他推荐联系人
消息
Gilead Sciences Spain 的最新新闻稿
- Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
- Gilead Sciences Announces Completion of Acquisition of CymaBay
- Gilead Sciences to Present at Upcoming Investor Conferences
- Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
- Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
- U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
- Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
- Gilead Sciences to Present at Upcoming Investor Conferences
- View more press releases Close
通过电子邮件
